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Abstract
Vaccinia virus (VACV) encodes an anti-apoptotic Bcl-2-like protein F1 that acts as an inhibitor of caspase-9 and of the Bak/
Bax checkpoint but the role of this gene in immune responses is not known. Because dendritic cells that have phagocytosed
apoptotic infected cells cross-present viral antigens to cytotoxic T cells inducing an antigen-specific immunity, we
hypothesized that deletion of the viral anti-apoptotic F1L gene might have a profound effect on the capacity of poxvirus
vectors to activate specific immune responses to virus-expressed recombinant antigens. This has been tested in a mouse
model with an F1L deletion mutant of the HIV/AIDS vaccine candidate MVA-C that expresses Env and Gag-Pol-Nef antigens
(MVA-C-DF1L). The viral gene F1L is not required for virus replication in cultured cells and its deletion in MVA-C induces
extensive apoptosis and expression of immunomodulatory genes in infected cells. Analysis of the immune responses
induced in BALB/c mice after DNA prime/MVA boost revealed that, in comparison with parental MVA-C, the mutant MVA-C-
DF1L improves the magnitude of the HIV-1-specific CD8 T cell adaptive immune responses and impacts on the CD8 T cell
memory phase by enhancing the magnitude of the response, reducing the contraction phase and changing the memory
differentiation pattern. These findings reveal the immunomodulatory role of F1L and that the loss of this gene is a valid
strategy for the optimization of MVA as vaccine vector.
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Introduction
The search for a safe and effective HIV vaccine able to induce
long-lived protective immunity has stimulated the development of
recombinant live vaccine candidates with good safety and
immunogenicity profiles. The recent Thai phase III clinical trial
(RV144) combining, in a prime-boost strategy, the recombinant
poxvirus vector ALVAC and the protein gp120 and showing
a 31.2% of protection against HIV infection [1], has raised
considerable interest in the use of improved attenuated poxvirus
recombinants as HIV vaccine candidates. Among poxviruses,
recombinants based on the highly attenuated strain MVA
expressing different HIV-1 antigens have been extensively studied
in preclinical [2,3,4] and clinical trials with encouraging results
[5,6,7,8,9,10,11,12].
MVA was derived from the Ankara strain of vaccinia virus
(VACV) after more than 500 passages on chicken embryo
fibroblast cells. During this extensive passage, six regions
(approximately 31 kb) were lost from the viral genome, resulting
in the deletion of a number of host-range restriction and
immunomodulatory genes [13,14]. As a result of the deletion of
host-range restriction genes, replication of MVA in most non-
avian cell types aborts at a late stage of the virus life cycle [15,16].
MVA provides a high level of gene expression and triggers strong
immune responses when delivering foreign antigens in animals and
humans [4,17,18,19]. However, further improvement of MVA-
based vaccines with enhanced magnitude, breadth, polyfunction-
ality and durability of the immune response is needed.
Virus detection by the infected cell often results in the induction
of apoptosis as an anti-viral mechanism to limit viral spread. For
this reason, viruses have evolved strategies that target key
components of the apoptotic cascade, including inhibitors of the
intrinsic pathway of apoptosis [20,21,22,23]. Apoptosis is a com-
plex and highly regulated mechanism of programmed cell death
that is mediated by a family of cysteine proteases, or caspases,
whose activation is triggered by a number of external or cellular
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signals [24,25,26]. In vivo, the initial non-specific anti-viral effect of
apoptosis induction can be potentiated by the capture of apoptotic
bodies by dendritic cells (DCs). This uptake and processing of
apoptotic infected cells by DCs can enhance MHC class I
presentation of viral antigens and increase the immune response,
phenomenon known as cross-presentation [27]. In this context, the
induction of apoptosis by deletion of viral anti-apoptotic genes in
recombinant MVA expressing heterologous antigens could be
a strategy to enhance the immunogenicity against a vaccine
antigen.
Vaccinia virus (VACV), the prototypic member of the Poxviridae
family, expresses a mitochondrial-associated inhibitor of apoptosis
encoded by F1L gene. The F1L open reading frame in VACV
strain Copenhagen encodes a tail-anchored protein of 226 amino
acids that localizes to the outer mitochondrial membrane, where it
inhibits the loss of the inner mitochondrial membrane potential
and the release of cytochrome c in response to a wide variety of
apoptotic stimuli [28,29,30]. Its C-terminal region contains
a hydrophobic 12-amino acid transmembrane domain flanked
by positively charged lysines followed by an 8-amino acid
hydrophilic tail, which are necessary for mitochondrial targeting
as well as for the anti-apoptotic function [29]. The F1L open
reading frame is highly conserved between the MVA genome
(ORF 029) and VACV strain Copenhagen (98% amino acid
identity) [13]. The anti-apoptotic mechanism of action of F1 has
been extensively studied. The success of the apoptosis induced by
the mitochondrial pathway depends on the balance between pro-
and anti-apoptotic members of the Bcl-2 (B-cell lymphoma-2)
family of proteins, which are typically characterized as containing
one or more Bcl-2 homology (BH) domains [31]. F1 has been
reported to interact with the BH3 domain of the pro-apoptotic
protein Bak, inhibiting tBid-induced Bak activation [30,32]. This
interaction is mediated by highly divergent BH domains in F1 [33]
that were verified by the crystal structure of F1 protein from MVA
strain [34]. This structure confirmed that despite a lack of
apparent sequence homology to Bcl-2 proteins, F1 adopts a Bcl-2-
like fold. In addition to interacting with Bak, F1 has also been
reported to associate with the BH3-only protein Bim indirectly
inhibiting the activation of the pro-apoptotic protein Bax following
an apoptotic stimulus [35,36]. In this context, it has been proposed
that F1 orthologs represent the only orthopoxvirus Bcl-2-like
proteins to directly inhibit the Bak/Bax checkpoint [37]. F1 has
also been reported to bind to and inhibit caspase-9, the apical
protease in the intrinsic (mitochondrial) pathway, independent of
its interactions with pro-apoptotic Bcl-2 family proteins [38]. An
N-terminal a helix of F1 preceding the Bcl-2-like fold is
responsible for this caspase-9 binding and inhibition [38,39].
Therefore, F1 is the first viral anti-apoptotic protein described that
functions both as a suppressor of pro-apoptotic Bcl-2 family
proteins and as an inhibitor of caspase-9, thereby blocking two
sequential steps in the mitochondrial apoptotic pathway. A
molecular framework of how cells detect MVA infection in vitro
and induce apoptosis and how the virus blocks apoptosis by
interfering with critical steps of its signal transduction has been
previously reported using either MVA wt or F1L deletion mutant
[36,40].
Because MVA infection of different human cell lines induces
apoptosis and cross-presentation by DCs [41] and MVA
recombinants expressing HIV antigens have shown good immu-
nogenicity profiles in animal models and in humans [42,43], in the
present study we have asked to what extent enhanced apoptosis
induction by deletion of F1L gene can improve the capacity of
MVA-C, an attenuated poxvirus vector expressing HIV-1 Env and
Gag-Pol-Nef antigens from clade C [44], to activate specific
adaptive and memory immune responses to HIV-1 antigens in
a BALB/c mouse model.
Results
Generation and in vitro Characterization of MVA-C-DF1L
Deletion Mutant
MVA-C-DF1L deletion mutant, in which F1L ORF has been
substituted for a rsGFP expression cassette, was generated as
described under Materials and Methods using as parental virus the
recombinant MVA-C that expresses the HIV-1 Env and Gag-Pol-
Nef antigens from clade C [44]. The correct deletion of F1L was
confirmed by PCR using primers annealing in F1L flanking
sequences. As shown in Figure 1B, F1L ORF has been successfully
deleted and substituted for the rsGFP expression cassette and no
wild-type contamination was present in MVA-C-DF1L prepara-
tion. To determine if F1L gene affects virus replication in cell
culture, we compared the growth kinetics of MVA-C-DF1L
deletion mutant with its parental virus MVA-C in CEF cells.
Figure 1C shows that the kinetics of growth were similar between
parental and F1L deletion mutant. This indicates that F1L gene is
not required for virus replication in cultured cells and its deletion
does not affect virus growth kinetics.
MVA-C-DF1L Deletion Mutant Expresses HIV-1 Antigens
in a Stable Manner
When considering the use of a recombinant vector as a vaccine,
it is critical to ensure that recombinants can be grown to large
scale without loss of the transgene. Therefore, a stability test was
performed. Monolayers of DF-1 cells were infected with MVA-C-
DF1L at passage 11 and 30 individual plaques were picked up,
grown and analyzed by Western-blot with specific anti-gp120 or
anti-p24 antibodies. As shown in Figure 2A, out of 30 isolated
plaques none of them represent wild-type reversion. All (100%)
express the correct full-length gp120 protein and for Gag-Pol-Nef
(GPN) polyprotein, 27 (90%) express the correct full-length
polyprotein and 3 (10%) express a truncated form. Similar
percentages were obtained with the parental virus MVA-C (data
not shown). These results reveal that MVA-C-DF1L deletion
mutant is genetically stable and that gp120 is slightly more stable
than GPN.
To identify the mutations present in truncated forms of GPN
polyprotein, viral DNA extracted from DF-1 cells infected with
plaques 19 or 26 of MVA-C-DF1L was used as template to amplify
and sequence different regions of the polyprotein (Figure 2B).
Plaque 10 was not analyzed because it showed the same expression
pattern than plaque 19. In the case of plaque 19, oligonucleotides
sgpn-fwd-802 and sgpn-rev-2198 were used to amplify a 1414 bp-
product comprising from positions 802 to 2198 of the entire
4254 bp sequence of GPN. This PCR product was sequenced with
the same primers used for PCR amplification and, as shown in
Figure 2C, an additional cytosine was inserted in a region of 8
consecutive cytosines at position 1355–1362. Wild-type GPN
sequence comprises 4254 bp encoding a polyprotein of 1417
residues and 150 KDa of molecular weight. In the case of plaque
19, the additional cytosine produces a frame-shift and a premature
stop codon at position 3216, encoding a polyprotein of 1071
residues and 113 KDa of molecular weight. In the case of plaque
26, oligonucleotides sgpn-fwd-2018 and sgpn-rev-3820 were used
to amplify a 1819 bp-product comprising from positions 2018 to
3820 of the entire 4254 bp sequence of GPN. This PCR product
was sequenced with primers sgpn-fwd-2415 and sgpn-rev-3401
and an additional cytosine was inserted in a region of 6
consecutive cytosines at position 3136–3141 (Figure 2C). This
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additional cytosine generates a frame-shift and a premature stop
codon at position 3216, producing a polyprotein of 1071 residues
and 113 KDa of molecular weight. As shown in Figure S1, GPN
sequence contains cytosine-rich regions. It comprises 14 regions of
5 consecutive cytosines, 1 region of 8 consecutive cytosines
(cytosine insertion detected in plaque 19) and 1 region of 6
consecutive cytosines (cytosine insertion detected in plaque 26).
Probably, these cytosine-rich regions serve as hot spots for
spontaneous point mutations [45], turning GPN into less stable
protein than gp120, which lacks cytosine-rich regions. Nonethe-
less, the insertion cassette (gp120-GPN) placed in the TK locus
was highly stable within the MVA genome.
Apoptosis Induction by MVA-C-DF1L Deletion Mutant
If the role of F1 is to block apoptosis triggered in the cell as
a response to VACV infection, the deletion mutant MVA-C-DF1L
would be expected to induce apoptosis. To confirm this, we
analyzed the PARP cleavage by Western-blot and the integrity of
the cell membrane by Annexin V binding assay. The cleavage of
PARP [poly (ADP-ribose) polymerase] commonly occurs in
apoptotic cells by the activation of caspases. In human PARP,
the cleavage separates PARPs amino-terminal DNA binding
domain (24 KDa) from its carboxy-terminal catalytic domain
(89 KDa) [46]. Therefore, PARP cleavage serves as a marker of
cells undergoing apoptosis and was analyzed by Western-blot in
HeLa cells mock-infected or infected with MVA wt, MVA-C or
MVA-C-DF1L (5 PFU/cell) at 16 hours post-infection. The
antibody used recognizes both forms of the protein, full-length and
cleaved PARP. As shown in Figure 3A, the 116-KDa full-length
PARP was mostly cleaved (89 KDa) in cells infected with MVA-C-
DF1L while in cells mock-infected or infected with MVA wt or
MVA-C this cleavage was reduced.
Changes in the asymmetry of the cell membrane associated with
the externalization of phosphatidylserine (PS) are one of the events
observed in a cell undergoing apoptosis. Annexin V has high
affinity to PS so, together with propidium iodide (PI), it is a useful
tool to quantify apoptosis by flow cytometry. This assay allows to
determine the percentage of viable cells (both Annexin V and PI
negative), early apoptotic cells (Annexin V positive, PI negative)
and cells that are in late apoptosis or already dead by apoptotic or
necrotic pathways (both Annexin V and PI positive). Thus, HeLa
or 3T3 cells mock-infected or infected with MVA wt, MVA-C or
MVA-C-DF1L at 5 PFU/cell were stained with Annexin V and
propidium iodide at 16 hours post-infection as described under
Materials and Methods. As this analysis does not distinguish
between cells that have undergone apoptosis versus those that have
died as a result of a necrotic pathway, we have determined the
percentage of early apoptotic cells (Annexin V positive, PI
negative). As shown in Figure 3B (upper panels), 29% (HeLa) or
19% (3T3) of cells infected with MVA-C-DF1L were Annexin V
positive/PI negative, which represents a significant increase with
respect to MVA-C-infected cells (HeLa: 17%; 3T3:1%) (p,0.001).
The percentage of total death (Annexin V and PI positive cells)
was also enhanced in MVA-C-DF1L-infected HeLa or 3T3 cells
(data not shown). Finally, we wanted to confirm this enhanced
apoptosis by F1L deletion in a more physiological system so we
performed the Annexin V/PI assay in mock-infected or MVA wt,
MVA-C or MVA-C-DF1L-infected murine bone marrow-derived
dendritic cells (mDCs) at 5 PFU/cell for 16 hours. As shown in
Figure 3 (lower panel), the percentage of early apoptotic cells is
significantly increased in the case of MVA-C-DF1L-infected
mDCs (25%) compared with the percentages obtained in MVA
wt (7%) or MVA-C (4%)-infected mDCs (p,0.001), as previously
observed for the case of HeLa and 3T3 cell lines. These results
indicate that F1L deletion from MVA markedly increases the levels
of apoptosis.
MVA-C-DF1L Up-regulates Type I IFN and Pro-
inflammatory Cytokine Expression in Murine
Macrophages and Dendritic Cells
Since mitochondria are not only involved in the control of the
metabolic status of the cell but are also a hub for cell death and
innate immunity signaling pathways [47], we wanted to determine
whether F1 impairs the response of innate immune cells to MVA-
C infection. We analyzed by real-time PCR and ELISA the
expression of type I IFNs (IFN-a and IFN-b), pro-inflammatory
cytokines (IL-1b, TNF, IL-6, IL-12p40) and chemokines (MIP-1a)
by murine bone marrow-derived macrophages (BMDMs) and
dendritic cells (BMDCs) mock-infected or infected with MVA-C or
MVA-C-DF1L (Figure 4). Compared to MVA-C, MVA-C-DF1L
markedly up-regulated type I IFN, cytokine and chemokine
expression in both BMDMs and BMDCs. These differences in
apoptosis induction and cytokine/chemokine expression may have
an impact on the immunogenicity of the vector. Thus, we next
analyzed the immune response elicited in mice by MVA-C-DF1L
deletion mutant.
Deletion of the Viral Gene F1L in MVA-C Induces High,
Broad and Polyfunctional HIV-1-specific T Cell Adaptive
Immune Responses
To assay in vivo the effect of F1L deletion on the cellular
immunogenicity against HIV-1 antigens, we analyzed the HIV-1-
specific immune responses elicited by MVA-C-DF1L in mice using
a DNA prime/Poxvirus boost approach since it has been
extensively reported that this heterologous immunization protocol
is more immunogenic than either component alone to activate T
cell responses to HIV-1 antigens [44,48,49]. BALB/c mice, 6 in
each group, were immunized according to the schedule shown in
Figure 5A. Animals primed with sham DNA (DNA-w) and boosted
with the non-recombinant MVA wt were used as control group.
Figure 1. Generation and in vitro characterization of MVA-C-DF1L deletion mutant. (A) Scheme of construction of the plasmid transfer
vector pGem-RG-F1L. The plasmid transfer vector pGem-RG-F1L was obtained by sequential cloning of markers dsRed2 and rsGFP and F1L
recombination flanking sequences into the plasmid pGem-7Zf. The dsRed2 gene under the control of the synthetic early/late (E/L) promoter was
excised from plasmid pG-dsRed2 and inserted into pGem-7Zf to generate pGem-Red. The rsGFP gene under the control of the synthetic E/L promoter
was amplified by PCR from plasmid pG-dsRed2, digested and inserted into the plasmid pGem-Red to generate pGem-Red-GFP. MVA genome was
used as template to amplify the left flanking sequence of F1L gene. The PCR product was digested and inserted into pGem-Red-GFP previously
digested and dephosphorylated by incubation with Calf intestinal Alkaline Phosphatase (CIP) to generate the plasmid pGem-RG-fiF1L. The right
flanking sequence of F1L gene was amplified by PCR from MVA genome. The PCR product was digested and inserted into plasmid pGem-RG-fiF1L to
generate the plasmid transfer vector pGem-RG-F1L. (B) Confirmation of F1L gene deletion by PCR analysis. Viral DNA was extracted from DF-1 cells
infected with MVA wt or MVA-C-DF1L at 5 PFU/cell. Primers fdF1L-S and fiF1L-BR spanning F1L flanking sequences were used for PCR analysis of F1L
locus. In parental MVA, a 1380 bp-product is obtained while in deletion mutant a unique 1529 bp-product is observed. (C) Analysis of virus growth of
MVA-C-DF1L in CEF cells. Monolayers of CEF cells were infected with MVA-C or MVA-C-DF1L at 0.01 PFU/cell. At different times post-infection (0, 24,
48 and 72 hours), cells were collected and infectious viruses were quantified by immunostaining assay.
doi:10.1371/journal.pone.0048524.g001
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Figure 2. Analysis of the stability of gp120 and GPN proteins expressed by MVA-C-DF1L. (A) Thirty individual plaques from MVA-C-DF1L
were grown in DF-1 cells, lysed, proteins fractionated by SDS-PAGE and analyzed by Western-blot with specific antibodies. The expression of gp120 or
GPN proteins in mock-infected cells or cells infected with MVA wt, MVA-C or with individual plaques from MVA-C-DF1L (1–30) is shown. Arrows
indicate the correct size of gp120 and GPN proteins. (B) Schematic representation of the HIV-1 inserts within the TK viral locus of MVA-C. The
positions and sequences of the different sets of primers used for PCR analysis and sequencing of GPN polyprotein and the expected sizes of PCR
products are represented. (C) Identification of mutations of GPN polyprotein. Viral DNA extracted from DF-1 cells infected with plaques 19 or 26 of
MVA-C-DF1L was used as template to amplify and sequence different regions of GPN polyprotein. In plaque 19, one cytosine insertion was identified
at position 1355–1362 producing a frame-shift and a premature stop codon at position 3216. In plaque 26, one cytosine insertion was identified at
position 3136–3141 producing a frame-shift and a premature stop codon at position 3216.
doi:10.1371/journal.pone.0048524.g002
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Figure 3. Analysis of apoptosis induced by MVA-C-DF1L deletion mutant. (A) PARP cleavage was analyzed by Western-blot in HeLa cells
mock-infected or infected with MVA wt, MVA-C or MVA-C-DF1L at 5 PFU/cell for 16 hours. Detection of cellular b-actin protein was used as an internal
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Ten days after the boost (day 25), the adaptive T cell immune
responses in 3 mice of each group were measured by poly-
chromatic ICS assay after the stimulation of splenocytes with HIV-
1 Env-1, Pol-1 or Pol-2 peptides. These 3 peptides were selected
for the ICS analysis because they have been finely mapped and
described as the most immunogenic MHC class I-restricted CTL
peptides in the BALB/c model against the same clade C construct
[50]. As shown in Figure 5B, the magnitudes of the total HIV-1-
specific CD8 T cell response, determined as the sum of the
individual responses obtained for Env-1, Pol-1 and Pol-2 peptides,
were significantly higher in the groups immunized with MVA-C or
MVA-C-DF1L than that obtained in the control group DNA-w/
MVA wt (p,0.001). Furthermore, the magnitude of the HIV-1-
specific CD8 T cell response in the group immunized with MVA-
C-DF1L was significantly higher than that obtained in the group
DNA-C/MVA-C (p,0.001). This enhancement in the magnitude
of the CD8+ T cell response observed in the animals immunized
with MVA-C-DF1L was clearly directed against the Pol protein
since the anti-Env response was not significantly affected.
Representative profiles of Pol-induced CD8 T cell responses were
shown in Figure 5C. Similar findings were observed in two
independent experiments.
The quality of a T cell immune response can be characterized in
part by the pattern of cytokine secretion. On the basis of the
analysis of IFN-c, IL-2 and TNF-a production, seven different
HIV-1-specific CD8 T cell populations were identified (Figure 6).
The percentages of cells producing cytokines obtained in the
DNA-w/MVA wt control populations were subtracted in the
DNA-C/MVA-C or DNA-C/MVA-C-DF1L immunization
groups in order to remove the non-specific responses detected as
background. Vaccine-induced CD8 T cell responses were highly
polyfunctional in both immunization groups, with more than 75%
of CD8+ T cells exhibiting two or three functions. CD8+ T cells
producing IFN-c+IL-2+TNF-a, IFN-c+TNF-a and only TNF-a or
IFN-c were the most representative populations induced by the
parental MVA-C and the deletion mutant MVA-C-DF1L, but the
absolute frequencies of each population were significantly higher
in the group boosted with MVA-C-DF1L compared with the
parental MVA-C (Figure 6).
Since CD8 anti-Gag responses have been associated with better
control of HIV/AIDS disease in individuals with chronic HIV-1
infection [51], we decided to determine the magnitude of the
response triggered by Gag antigen by ELISPOT assay. Spleno-
cytes isolated from immunized animals were stimulated with the
HIV-1 peptide pools Gag-1, Gag-2 and GPN-1, which spanned
the entire Gag and part of Pol antigens included in the
immunogens. As shown in Figure S2, the magnitude of the total
Gag-specific T cell response, determined as the sum of the
individual responses obtained for the different peptide pools, was
significantly higher in the group immunized with MVA-C-DF1L
than in the group immunized with DNA-C/MVA-C (p,0.001).
Overall, these results indicate that deletion of F1L gene from
MVA-C genome improved the magnitude of the HIV-1-specific
adaptive CD8 T cell immune response and maintained the
polyfunctional profile observed with the parental MVA-C. Since
the contribution of the DNA prime is the same for MVA-C or
MVA-C-DF1L immunization groups, the differences observed
should be attributed to the F1L deletion.
Deletion of the Viral Gene F1L Impacts on the CD8 T Cell
Memory Phase of the Immune Response
Phenotypic analysis of memory vaccine-induced T cell response
was performed 53 days after the last immunization by poly-
chromatic ICS assay in the 3 mice left in each group (n = 3).
Splenocytes from immunized mice were stimulated with the HIV-
1 peptides Env-1, Pol-1 or Pol-2 for 6 hours and stained with
specific antibodies to identify CD8 T cell lineage, responding cells
(IFN-c, IL-2 and TNF-a) as well as memory stages (CD44 and
CD62L). As shown in Figure 7A, the magnitudes of the memory
HIV-1-specific CD8 T cell response, determined as the sum of the
individual responses obtained for Env-1, Pol-1 or Pol-2 peptides,
were significantly higher in the groups boosted with the parental
(MVA-C) or the deletion mutant (MVA-C-DF1L) than in the
control group DNA-w/MVA wt (p,0.001). Additionally, the
magnitude of the memory HIV-1-specific CD8 T cell response in
the group immunized with MVA-C-DF1L was significantly higher
than that obtained in the group DNA-C/MVA-C (p,0.001). This
enhancement in the magnitude of the CD8 T cell response
observed in the animals immunized with MVA-C-DF1L was
directed against both Env and Pol HIV-1 proteins but with
preference towards Pol since individual responses against Env-1,
Pol-1 or Pol-2 peptides were 2, 3 or 6-fold higher than in mice
immunized with MVA-C, respectively.
Contraction of the CD8+ T cell pool, determined as the ratio of
total HIV-1 positive cells at days 10 and 53 post-boost, was
significantly reduced (p,0.001) in the group of mice inoculated
with the deletion mutant MVA-C-DF1L in comparison with
animals immunized with the parental MVA-C (Figure 7B).
We also determined the phenotype of the memory response by
measuring the expression of CD62L and CD44 in the HIV-1-
specific CD8 T cells. CD62L is a key marker that discriminates the
effector and central memory T cell subpopulations in combination
with CD44, which is expressed at high levels in all effector and
central memory but not in naı¨ve T cells [52]. Thus, the effector
memory T cells (TEM) have a CD44highCD62L2 phenotype
whereas the central memory T cells (TCM) are CD44highCD62L+.
For CD8 T cells, the HIV-1-specific memory responses elicited by
MVA-C and MVA-C-DF1L were predominantly TEM but some
differences were observed between both groups. After MVA-C
boost, 67.9% and 89.8% of the CD8+ T cells against Pol-1 and
Pol-2 peptides respectively were TEM, whereas the deletion of
F1L increased these populations up to 90% (94.3% and 97%)
(Figure 7C). Overall, these results indicated that single deletion of
the viral gene F1L impacts on the CD8 T cell memory phase of the
immune response enhancing the magnitude of the response,
reducing the contraction phase and changing the memory
differentiation pattern.
Since cells infected with MVA-C release monomeric gp120 [44]
and it is generally accepted that both cellular and humoral arms of
the immune system are necessary to control HIV infection [53],
we quantified by ELISA the Env-specific IgG binding antibodies
in the serum of immunized animals during the memory phase of
the immune response. We observed that in the group boosted with
loading control. (B) Annexin V binding assay of HeLa, 3T3 cells or murine DCs infected with MVA wt, MVA-C or MVA-C-DF1L at 5 PFU/cell. At 16 hours
post-infection, the infected cells were stained with Annexin V and propidium iodide as described under Materials and Methods and the percentages
of early apoptotic cells (Annexin V positive, PI negative) were determined by flow cytometry. All data are mock-infected cells-subtracted. HeLa or 3T3
cells treated with staurosporine (0.5 mM) were used as positive control (not shown). *** p,0.001. p value indicates significantly higher response
compared to MVA wt or MVA-C-infected cells.
doi:10.1371/journal.pone.0048524.g003
Impact of F1L Deletion on MVA-C Immunogenicity
PLOS ONE | www.plosone.org 7 October 2012 | Volume 7 | Issue 10 | e48524
Figure 4. MVA-C-DF1L deletion mutant enhances the production of type I IFNs and cytokines in murine macrophages (A) and
dendritic cells (B). BMDMs or BMDCs were mock-infected (0) or infected with MVA-C or MVA-C-DF1L at 1 or 5 PFU/cell for 6 hours (upper panels) or
24 hours (lower panels). IFN-a, IFN-b, IL-1b, TNF, IL-6, IL-12p40 and MIP-1a mRNA (upper panels) and protein (lower panels) levels were quantified by
RT-PCR and ELISA, respectively. mRNA results are expressed as the ratio of the gene of interest to Hprt mRNA levels. A.U: arbitrary units. ELISA results
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the F1L deletion mutant, the levels of anti-gp120 antibodies were
higher than those obtained in animals immunized with the
parental MVA-C, although the difference was not statistically
significant (data not shown).
Discussion
A number of unique features make poxvirus recombinants good
candidates as vaccine vectors and therefore members of the
Poxviridae family are being widely used in the prevention and
treatment of emergent infectious diseases and cancer, with an
increasing interest focused on the highly attenuated ALVAC,
MVA and NYVAC strains [42,43]. Although these attenuated
VACV strains exert good safety and immunogenicity profiles, the
development of more efficient candidate vectors that enhance the
magnitude, breadth, polyfunctionality and durability of the
immune response against heterologous antigens is needed,
especially after the 31.2% of protection against HIV infection
obtained in the recent phase III clinical trial (RV144) in Thailand
using a combination of a recombinant ALVAC and the protein
gp120 [1]. One strategy to afford this objective consists in the
removal of specific viral immunomodulatory genes involved in the
inhibition of the host anti-viral response. This methodology has
been successfully used for MVA and NYVAC vectors
[3,54,55,56,57,58,59,60,61]. Here, we have evaluated another
different approach based on the removal of a viral inhibitor of
apoptosis with the aim to optimize poxvirus-based vectors.
It has been previously reported that DCs that have phagocy-
tosed apoptotic infected cells can cross-present viral or tumor
antigens to cytotoxic T cells and induce a cytotoxic response
[27,62]. Therefore, we have examined the effect of the deletion of
the viral anti-apoptotic gene F1L on the immunogenicity of the
HIV/AIDS vaccine candidate MVA-C in a BALB/c mouse
model. The MVA-C recombinant, expressing the HIV-1 gp120
and Gag-Pol-Nef proteins from clade C, has been previously
characterized [44,63] and its immunogenic potential has been
reported in the murine model [44].
In the present study, we have shown that viral gene F1L does
not affect virus replication nor HIV-1 antigen expression in
cultured cells and its deletion in MVA-C increases the percentage
of early apoptotic cells in murine and human cell lines and in bone
marrow-derived dendritic cells and enhances the expression of
type I IFN and pro-inflammatory cytokine genes in murine
macrophages and dendritic cells. Using a DNA-C prime/MVA-C
boost protocol in BALB/c mice, we have observed that deletion of
F1L from MVA-C genome, improves the magnitude of the HIV-
1-specific CD8 T cell adaptive and memory immune responses
maintaining a highly polyfunctional profile. This enhancement in
the HIV-1-specific CD8 T cell responses induced in animals
boosted with the MVA-C-DF1L deletion mutant might be
attributed to the increased cross-presentation of viral antigens by
DCs that have engulfed apoptotic MVA-C-DF1L-infected cells.
Antigens derived from viral infections can be recognized by
cytotoxic T cells (CTLs) if such viral antigens are presented by
DCs, the most potent antigen-presenting cells (APCs) and the only
cell type capable of activating naı¨ve T cells [64,65,66]. DCs are
specialized to process and present in a major histocompatibility
complex (MHC) class I-restricted manner viral antigens synthe-
sized endogenously within the infected DC itself (direct pre-
sentation) or exogenously from acquired antigens produced by
other infected cells (cross-presentation) [67]. Although MVA has
the ability to infect DCs which are capable to express and present
viral and heterologous antigens to CTLs [68], the abortive viral
cell cycle at early stages, the apoptosis induced in DCs after MVA
infection (even more accelerated in the case of DCs infected with
MVA-C-DF1L) and the host cell protein synthesis shutdown, point
to the conclusion that cross-presentation could be the dominant
pathway for the priming of CD8+ T cells in response to MVA
infection [69,70]. In this context, cross-presentation of tumor and
viral antigens expressed by different poxviruses, including MVA,
has been extensively documented [41,71,72].
According to the poxvirus inoculation route used in this
immunization schedule (i.p.), the effect of F1L gene deletion on
immunogenicity against HIV-1 antigens, should be explained by
the impact of enhanced apoptosis induction in the cell types
present in the peritoneal cavity, which are mainly B cells,
macrophages and granulocytes and, to a lesser extent, T cells
[73]. It has been reported that MVA preferentially infects DCs,
monocytes/macrophages and B cells in mice and humans
[74,75,76,77] and induces apoptosis in these cell types [40,77].
In this context, cell death induction by MVA may be desirable for
antigen uptake and cross-presentation by uninfected DCs and this
cross-presentation could be further enhanced in animals immu-
nized with MVA-C-DF1L since F1L deletion mutant triggers
apoptosis earlier than MVA-C. In this context, it has been
reported that human DCs exposed to MVA initiate apoptosis at
least 1 day earlier that DCs exposed to VACV [70] and this early
apoptosis induction may explain, at least in part, why the
immunogenicity of MVA is equal to or greater than that of
replication-competent strains of VACV [78,79,80,81].
On the other hand, MVA has been shown to induce a robust
innate immune response characterized by the production of pro-
inflammatory cytokines (TNF, IL-1b, IL-6, IL-12p40), chemokines
(IP-10/CXCL10, RANTES/CCL5, MCP-5/CCL12, MIP-2/
CXCL2) and type I interferon (IFN-b) in murine peritoneal cells
and peritoneal lavage fluid [82]. In the present study, we have
demonstrated that MVA-C is also able to induce the secretion of
type I IFNs, chemokines (MIP-1a) and pro-inflammatory
cytokines (TNF, IL-1b, IL-6, IL-12p40) in murine bone marrow-
derived macrophages and dendritic cells and that deletion of F1L
gene enhanced this type I IFN and cytokine/chemokine pro-
duction. MVA infection has also been reported to induce robust
production of chemokines in human macrophages/monocytes
[82,83] and this observation correlated with the results obtained in
our study in which MVA-C-DF1L infection of human THP-1
macrophages markedly up-regulated IFN-b as well as IL-8 and IP-
10 chemokines production (data not shown). In the context of an
intraperitoneal immunization with MVA-C-DF1L deletion mu-
tant, the increased secretion of pro-inflammatory cytokines and
chemokines by infected macrophages could produce an enhanced
recruitment of immature DCs and lymphocytes, thus generating
an appropriate environment for the cross-presentation of vaccine-
encoded antigens. Immature DCs that have engulfed apoptotic
MVA-C-DF1L-infected cells can also migrate to the lymph nodes,
maturing in route, and activate antigen-specific CD8 T cells. The
recruitment of immature DCs to the site of infection may also
occur when the number of apoptotic cells overcomes the scavenger
potential of macrophages, which may occur in mice immunized
with MVA-C-DF1L. Therefore, immunogenicity against the dying
are means6 SD of duplicate samples from one experiment and are representative of two experiments. * p,0.05 for all conditions comparing MVA-C-
DF1L to MVA-C at the same MOI.
doi:10.1371/journal.pone.0048524.g004
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Figure 5. Adaptive HIV-1-specific T cell immune response elicited by F1L deletion mutant. (A) Schematic diagram showing the
vaccination schedule followed in the study and the immunogenicity endpoints. (B) Magnitude of the vaccine-specific CD8 T cell response. The HIV-1-
specific CD8 T cells were measured 10 days after the last immunization by ICS assay following stimulation with the different HIV-1 peptides in 3 mice
of each group (n = 3). The total value in each group represents the sum of the percentages of CD8+ T cells secreting IFN-c and/or IL-2 and/or TNF-
a against Env-1+Pol-1+Pol-2 peptides. All data are background-subtracted. (C) Flow cytometry profiles of vaccine-induced CD8 T cell responses
against Pol-1 or Pol-2 peptides. *** p,0.001. p value indicates significantly higher response compared to DNA-C/MVA-C immunization group.
doi:10.1371/journal.pone.0048524.g005
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cells might also be influenced by the relative amounts of cells
undergoing apoptosis at a given time.
Taking together all the above considerations, the observation
that the magnitude of the HIV-1-specific CD8 T cell adaptive
response in the group immunized with MVA-C-DF1L was
significantly higher than that obtained in the group DNA-C/
MVA-C (p,0.001) could be attributed to an enhanced cross-
presentation of HIV-1 antigens by F1L gene deletion-induced
apoptosis of infected cells together with the increased pro-
inflammatory environment generated. The observation that this
enhancement in the magnitude of the CD8 T cell response was
clearly directed against the Pol protein is in concordance with the
intracellular nature of the Gag-Pol-Nef immunogen. Immuniza-
tion with MVA-C-DF1L does not decrease the polyfunctional
profile of the HIV-1-specific CD8 T cells compared to that
obtained with MVA-C inoculation, since vaccine-induced CD8 T
cell responses were highly polyfunctional in both immunization
groups, with more than 75% of CD8+ T cells exhibiting two or
three functions.
During the memory phase of the immune response, the
magnitude of the HIV-1-specific CD8 T cell response in the
group immunized with MVA-C-DF1L was also significantly
higher than that obtained in the group DNA-C/MVA-C, again
with a clear preference towards Pol antigen (p,0.001). This
increase in the magnitude of the memory response could be
a consequence of the enhanced HIV-1-specific CD8 T cell
response elicited during the adaptive phase of the immune
response. Additionally, the CD8+ T cells activated by F1L deletion
mutant during the memory phase have enhanced differentiation to
an effector memory phenotype (TEM) compared with the CD8+ T
cells activated by the parental MVA-C, particularly against Pol-1
peptide. This is of particular relevance since an important role of
the effector memory T cells on the early control of highly
pathogenic SIV has been reported [84,85].
The effect on the HIV-specific immune responses elicited by
attenuated strains of VACV expressing different HIV-1 antigens
and lacking several immunomodulatory genes has been previously
reported in the context of DNA prime/Poxvirus boost immuni-
zation protocols. A recombinant MVA expressing Env and Gag-
Pol-Nef of HIV-1 from clade B (MVA-B) with A41L and B16R
genes deleted, has been shown to significantly enhance the
magnitude of the HIV-1-specific adaptive and memory T cell
responses [57]. The total magnitudes obtained with the double
deletion mutant were about 13% (adaptive phase) and 22%
(memory phase) compared with the 5% and 11% obtained in
animals immunized with the combination DNA-B/MVA-B,
respectively [57]. These enhanced HIV-1-specific immune
responses were mostly mediated by GPN-specific CD8+ T cells
while T cells induced by the parental MVA-B were mainly Env-
specific CD8+ T cells [57]. An enhancement in the HIV-1-specific
Figure 6. Functional profile of the adaptive HIV-1-specific CD8 T cell response in the different immunization groups. All the possible
combinations of the responses are shown on the x axis, whereas the percentages of the functionally distinct cell populations within the total CD8 T
cell population are shown on the y axis. Responses are grouped and color-coded on the basis of the number of functions. The non-specific responses
obtained in the control group DNA-w/MVA wt were subtracted in all populations. * p,0.05; *** p,0.001. p values indicate significantly higher
responses compared to DNA-C/MVA-C immunization group.
doi:10.1371/journal.pone.0048524.g006
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Figure 7. Memory response to HIV-1 peptides elicited by F1L deletion mutant. (A) Magnitude of vaccine-specific CD8 T cells. The HIV-1-
specific CD8 T cells were measured 53 days after the last immunization by ICS assay following stimulation with the different HIV-1 peptides in the 3
mice left in each group (n = 3). The values represent the sum of the percentages of positive T cells secreting IFN-c and/or IL-2 and/or TNF-a against
Env-1+Pol-1+Pol-2 peptides. All data are background-subtracted. (B) Fold contraction of the frequency of HIV-1-specific CD8 T cells following boost.
Fold contraction was calculated as a ratio of HIV-1-positive T cells at days 10 and 53 post boost. (C) Phenotypic profile of memory HIV-1-specific CD8 T
cells. Representative FACS plots showing the percentage of Env-1, Pol-1 or Pol-2-specific CD8 T cells with central memory (TCM, CD44highCD62L+) or
effector memory (TEM, CD44highCD62L2) phenotype. *** p,0.001. p values indicate significantly higher response (A) or lower fold contraction (B)
compared to DNA-C/MVA-C immunization group.
doi:10.1371/journal.pone.0048524.g007
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memory T cell response has also been reported in the case of an
MVA-B recombinant lacking C6L gene [3], with the HIV-1-
specific memory T cell immune response (11% vs. 3%) mainly
mediated by GPN-specific CD8+ T cells [3]. This immunodomi-
nance towards CD8+ GPN-specific T cell immune response is in
concordance with the results obtained with the F1L deletion
mutant in which 6% vs. 3% (adaptive phase) and 4% vs. 1%
(memory phase) of HIV-specific CD8+ T cells were mainly
directed against Pol antigen. The lower magnitudes obtained with
the F1L deletion mutant could be attributed to the more restricted
stimulation used (Env-1, Pol-1 or Pol-2 peptides compared with
a wide panel of Env, Gag and GPN peptide pools). This
modulation of the HIV-1-specific immune responses by the
removal of immunomodulatory genes has also been reported in
the case of DNA Prime/NYVAC boost immunization schedules.
NYVAC-C (expressing Env and Gag-Pol-Nef of HIV-1 from clade
C) deletion mutants lacking B19R and/or B8R genes, encoding
inhibitors of type I and type II IFNs, respectively, have also been
shown to improve the magnitude of HIV-1-specific CD8+ T cell
adaptive immune responses and to impact their memory phase
[61]. HIV-1-specific CD8+ T cell responses were higher in the
groups boosted with the NYVAC-C deletion mutants (2.5%–4%)
than in the group boosted with the parental NYVAC-C (1.7%)
and this enhancement is clearly directed against the Env pool [61].
However, during the memory phase of the immune response, the
patterns of CD8+ T cells were different between the vectors with
NYVAC-C, NYVAC-C-DB19R and NYVAC-C-DB8R/DB19R
inducing a higher percentage of GPN-specific CD8+ T cells
(NYVAC-C-DB8R/DB19R . NYVAC-C-DB19R) and NYVAC-
C-DB8R eliciting preferentially Env-specific CD8+ T cells [61].
The above observations show that the deletion of immunomod-
ulatory genes that antagonize host-specific immune responses
enhances the HIV-specific immune responses and suggest that
multiple combinations of such deletions could be a strategy for the
generation of optimized poxvirus-based HIV vaccine candidates.
In summary, the results of the present work indicate that single
deletion of the viral gene F1L improves the magnitude of the HIV-
1-specific CD8 T cell adaptive immune response and impacts on
the CD8 T cell memory phase increasing the magnitude of the
response, reducing the contraction phase and changing the
memory differentiation pattern by possibly enhancing the cross-
presentation of HIV-1 antigens by DCs mediated by apoptosis
induction.
These findings may have implications for vaccine design since
F1L deletion from MVA vaccines may constitute a mechanism to
deliver heterologous antigens in a manner that will promote cross-
presentation of such antigens and hence stimulating strong
immunity. The observation that F1 is currently the only VACV
Bcl-2-like protein with anti-apoptotic activity, since the other
proposed Bcl-2-like protein N1 has been reported to inhibit the
innate immunity signaling pathways that activate IRF-3 and NF-
kB transcription factors but not to inhibit apoptosis [37,86,87],
suggests that F1 can be considered both as an anti-apoptotic
protein and as an immune modulator. In summary, these findings
reveal the immunomodulatory role of F1 and that deletion of the
viral anti-apoptotic F1L gene could be a valid strategy for the
optimization of MVA as vaccine vector.
Materials and Methods
Ethics Statement
The animal studies were approved by the Ethical Committee of
Animal Experimentation (CEEA-CNB) of Centro Nacional de
Biotecnologia (CNB-CSIC, Madrid, Spain) in accordance with
national and international guidelines and with the Royal Decree
(RD 1201/2005) (Permit numbers: 152/07 and 080030) and by
the Office Ve´te´rinaire du Canton de Vaud, Switzerland (author-
izations nu 876.7 and 877.7).
Cells and Viruses
Primary chicken embryo fibroblasts (CEF), DF-1 cells (a
spontaneously immortalized chicken embryo fibroblast cell line,
ATCC, Cat. No. CRL-12203), 3T3 cells (a mouse fibroblast-
derived cell line, ATCC, Cat. No. CCL-92) and HeLa cells (a
human epithelial cervix adenocarcinoma, ATCC, Cat. No. CCL-
2) were grown in Dulbeccos modified Eagles medium (DMEM)
supplemented with 10% fetal calf serum (FCS). Murine bone
marrow cells were cultured for 7 days in IMDM (Invitrogen)
supplemented with 10% FCS containing 50 mM 2-mercaptoetha-
nol and monocyte-colony stimulating factor or granulocyte-
monocyte colony stimulating factor to obtain bone marrow-
derived macrophages (BMDMs) or dendritic cells (BMDCs),
respectively. All media were supplemented with 100 IU/ml of
penicillin and 100 mg/ml of streptomycin. Cells were maintained
in a humidified air 5% CO2 atmosphere at 37uC (or 39uC for DF-
1 cell line). Virus infections were performed with 2% FCS for all
cell types. The poxvirus strains used in this work include modified
vaccinia virus Ankara (MVA) obtained from the Ankara strain
after 586 serial passages in CEF cells (derived from clone F6 at
passage 585, kindly provided by G. Sutter, Germany) and MVA-C
expressing gp120 as a cell released product and Gag-Pol-Nef as an
intracellular polyprotein from the clade C CN54 HIV-1 isolate
[44], used as parental virus for the generation of the F1L deletion
mutant. All viruses were grown in CEF cells, similarly purified
through two 36% (w/v) sucrose cushions and titrated by
immunostaining plaque assay as previously described [81]. The
titration of the different viruses was performed at least three times.
Construction of Plasmid Transfer Vector pGem-RG-F1L
The plasmid transfer vector pGem-RG-F1L, used for the
construction of recombinant virus MVA-C-DF1L in which F1L
ORF has been replaced for a GFP expression cassette, was
obtained by the sequential cloning of four DNA fragments
containing dsRed2 and rsGFP genes and F1L recombination
flanking sequences into the plasmid pGem-7Zf(-) (Promega). The
dsRed2 gene under the control of the synthetic early/late
promoter (783 bp) was obtained by digestion of plasmid pG-
dsRed2 (encoding dsRed2 and rsGFP genes) with Xba I and Eco
RI and inserted into the Xba I/Eco RI-digested pGem-7Zf(-) to
generate pGem-Red (3755 bp). The rsGFP gene under the control
of the synthetic early/late promoter was amplified by PCR from
plasmid pG-dsRed2 with oligonucleotides GFP-C (59-
GTTGGATCGATGAGAAAAATTG-39) (Cla I site underlined)
and GFP-B (59-CTATAGGATCCTCAAGCTATGC-39) (Bam
HI site underlined) (828 bp), digested with Cla I and Bam HI and
inserted into plasmid pGem-Red previously digested with Cla I
and Bam HI to obtain pGem-Red-GFP (4555 bp). MVA genome
was used as template to amplify the left flank of F1L gene (351 bp)
with oligonucleotides fiF1L-BF (59-CATCGAGGATCCAC-
TATTGTTTAT-39) (Bam HI site underlined) and fiF1L-BR (59-
TTATAGGATCCCTCCAGGAGAAAG-39) (Bam HI site un-
derlined). This left flank was digested with Bam HI and cloned into
plasmid pGem-Red-GFP previously digested with the same
restriction enzyme to generate pGem-RG-fiF1L (4889 bp). The
right flank of F1L gene (382 bp) was amplified by PCR from MVA
genome with oligonucleotides fdF1L-S (59-CCAGTCCCGGGA-
GACTGTACAA-39) (Sma I site underlined) and fdF1L-C (59-
GATAATCGATTTTTTTTTAACACG-39) (Cla I site under-
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lined), digested with Sma I and Cla I and inserted into the Sma I/
Cla I-digested pGem-RG-fiF1L. The resulting plasmid pGem-
RG-F1L (5244 bp; Figure 1A) was confirmed by DNA sequence
analysis and directs the insertion of GFP gene into F1L locus of
MVA-C.
Construction of MVA-C-DF1L Deletion Mutant
MVA-C-DF1L was constructed using dsRed2 and rsGFP
proteins as fluorescent markers. 36106 DF-1 cells were infected
with 0.05 PFU/cell of MVA-C and transfected 1 hour later with
8 mg DNA of plasmid pGem-RG-F1L using Lipofectamine 2000
(Invitrogen) according to the manufacturers recommendations.
After 48 hours post-infection, the cells were harvested, lysed by
freeze-thaw cycling, sonicated and used for recombinant virus
screening. MVA-C-DF1L was selected from progeny virus by
consecutive rounds of plaque purification in DF-1 cells during
which plaques were screened for Red2/GFP fluorescence. In the
first three passages viruses from selected plaques expressed both
fluorescent proteins while in the last three passages (six passages in
total) viral progeny from selected plaques expressed only GFP due
to the loss of dsRed2 marker.
PCR Analysis of MVA-C-DF1L Deletion Mutant
To test the identity and purity of the recombinant virus MVA-
C-DF1L, viral DNA was extracted from DF-1 cells infected at 5
PFU/cell with MVA wt or MVA-C-DF1L. Cell membranes were
disrupted using sodium dodecyl sulphate (SDS) followed by
proteinase K treatment (0.2 mg/ml proteinase K in 50 mM
Tris-HCl pH 8, 100 mM EDTA pH 8, 100 mM NaCl and 1%
SDS for 1 hour at 55uC) and phenol extraction of viral DNA.
Primers fdF1L-S and fiF1L-BR spanning F1L flanking regions
were used for PCR analysis of F1L locus. The amplification
reactions were carried out with Platinum Taq DNA polymerase
(Invitrogen) according to the manufacturers recommendations.
Analysis of Virus Growth
To determine virus growth profiles, monolayers of CEF cells
grown in 12-well plates were infected in duplicate at 0.01 PFU/cell
with MVA-C or MVA-C-DF1L deletion mutant. Following virus
adsorption for 60 min at 37uC, the inoculum was removed. The
infected cells were washed once with DMEM without serum and
incubated with fresh DMEM containing 2% FCS at 37uC in a 5%
CO2 atmosphere. At different times post-infection (0, 24, 48 and
72 hours), cells were harvested by scraping (lysates at 56105 cells/
ml), freeze-thawed three times and briefly sonicated. Virus titers in
cell lysates were determined by immunostaining assay in DF-1
cells using rabbit polyclonal anti-vaccinia virus strain WR (Centro
Nacional de Biotecnologı´a; diluted 1:1000), followed by anti-
rabbit-HRP (Sigma; diluted 1:1000).
Genetic Stability of MVA-C-DF1L Deletion Mutant by HIV-
1 Antigens Expression Analysis
To analyze the stability of HIV-1 antigens expressed by F1L
deletion mutant, monolayers of DF-1 cells grown in 6-well plates
were infected with serial dilutions of purified MVA-C-DF1L. After
1 hour of virus adsorption, the virus inoculum was removed and
cells overlayed with agar. At 48 hours post-infection, cells were
stained with 0.01% neutral red (Sigma) and 15 hours later 30
individual plaques were picked up, resuspended in 0.5 ml of
DMEM, freeze-thawed three times and briefly sonicated. 0.2 ml of
each plaque was used for infection of DF-1 cells in 24-well plates.
At 72 hours post-infection, cells were lysed in Laemmli buffer
containing b-mercaptoethanol, cells extracts fractionated by 8%
SDS-PAGE and analyzed by Western-blot using rabbit polyclonal
anti-gp120 antibody (Centro Nacional de Biotecnologı´a; diluted
1:3000) or polyclonal anti-gag p24 serum (ARP 432, NIBSC,
Centralised Facility for AIDS reagent, UK; diluted 1:1000)
followed by anti-rabbit-HRP (Sigma; diluted 1:5000) to evaluate
the expression of gp120 and GPN proteins, respectively. The
immunocomplexes were detected by enhanced chemilumines-
cence (ECL, GE Healthcare).
Identification of GPN Mutations
Viral DNA was extracted by the method of SDS-Proteinase K-
Phenol from DF-1 cells infected with different isolated plaques of
MVA-C-DF1L and used as template to amplify specific regions of
GPN polyprotein. The amplification reactions were carried out
with Platinum Pfx DNA polymerase (Invitrogen) according to the
manufacturers recommendations. Different PCR products were
sequenced by Secugen, S.L. Primers used for PCR amplification
and sequencing are depicted in Figure 2B.
Measurement of Apoptosis by PARP Cleavage
The cleavage of poly ADP-ribose polymerase (PARP) was
analyzed by Western-blot at 16 hours post-infection in extracts
from HeLa cells grown in 12-well plates mock-infected or infected
with MVA wt, MVA-C or MVA-C-DF1L at 5 PFU/cell. Rabbit
polyclonal anti-human PARP (diluted 1:500) was supplied by Cell
Signaling and mouse monoclonal antibody against b-actin (diluted
1:2000), anti-rabbit-HRP (diluted 1:5000) and anti-mouse-HRP
(diluted 1:2000) were supplied by Sigma.
Measurement of Apoptosis by Annexin V binding Assay
Annexin V binding assay was performed in combination with
propidium iodide (PI) staining to monitor the integrity of the cell
membrane. 56105 HeLa, 3T3 cells or murine DCs were infected
with MVA wt, MVA-C or MVA-C-DF1L at 5 PFU/cell. Mock-
infected cells and cells treated with staurosporine (0.5 mM; Sigma)
were used as negative and positive controls, respectively. At 16
hours post-infection, floating and adhered cells were collected
from the wells by pipetting and centrifuged at 3000 rpm for 5 min
at 4uC. Cells were washed twice with cold phosphate buffered
saline (PBS) and resuspended in 0.1 ml of binding buffer (10 mM
Hepes pH 7.4, 140 mM NaCl, 5 mM CaCl2). Cells were stained
with Annexin V-Biotin (Beckman Coulter) for 15 min at 4uC in
the dark according to the manufacturers recommendations. After
one wash with binding buffer, cells were incubated with
Streptavidin-PE (Beckman Coulter, diluted 1:100) for 20 min at
room temperature. Finally, cells were washed once with binding
buffer and resuspended in 0.5 ml binding buffer containing PI
(1 mg/ml; Beckman Coulter). The percentage of apoptotic cells
was determined by flow cytometry. 16105 cells were acquired
using an LSRII flow cytometer (BD Biosciences). Analyses of the
data were performed using the FlowJo software version 8.5.3 (Tree
Star, Ashland, OR). Early apoptotic cells were defined as Annexin
V positive and PI negative.
RNA Analysis by Quantitative Real-time Polymerase
Chain Reaction
Total RNA was isolated using the RNeasy kit (Qiagen) from
murine BMDMs or BMDCs mock-infected or infected at 1 or 5
PFU/cell with MVA-C or MVA-C-DF1L for 6 hours. Reverse
transcription of 100 ng to 500 ng of RNA was performed using
the ImProm II RT System kit (Promega). Quantitative PCR was
performed with a 7500 Fast Real-Time PCR System (Applied
Biosystems) using the Power SYBR Green PCR Master Mix
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(Applied Biosystems). Expression levels of Ifna, Ifnb, Ccl3 (Mip1a,)
Il1b, Il6, Il12b, Tnf and Hprt genes were analyzed by real-time
PCR using specific oligonucleotides (sequences will be provided
upon request). Gene specific expression was expressed relative to
the expression of Hprt in arbitrary units (A.U.). All samples were
tested in duplicate and two different experiments were performed.
Measurement of Cytokine Production
A screening of mediators produced by murine BMDMs or
BMDCs mock-infected or infected at 1 or 5 PFU/cell with MVA-
C or MVA-C-DF1L for 24 hours was performed by ELISA.
Mouse IFN-a, IFN-b (Biomedical Laboratories), MIP-1a, IL-1b,
TNF, IL-6 and IL-12p40 (R&D systems) were quantified by
ELISA. All samples were tested in duplicate and two different
experiments were performed.
DNA Vectors
The two DNA constructs expressing the HIV-1 CN54gp120
(pcDNA-CN54gp120) and HIV-1 CN54Gag-Pol-Nef (GPN) poly-
protein (pcDNA-CN54GPN) have been previously reported [44].
Plasmids were purified using Maxi-prep purification kits (Qiagen)
and diluted for injection in endotoxin-free PBS.
Peptides
The HIV-1 peptides Env-1 (sequence: PADPNPQEM), Pol-1
(sequence: LVGPTPVNI) and Pol-2 (sequence: YYDPSKDLI)
were previously described as H-2d-Restricted CTL epitopes [50]
and were provided by the Proteomic service at the CNB-CSIC,
Spain. The HIV-1 peptide pools Gag-1, Gag-2 and GPN-1 were
provided by the EuroVacc Foundation and were previously
described [44]. They spanned the entire HIV-1 Gag and part of
Pol antigens included in the immunogens as consecutive 15-mers
overlapping by 11 amino acids.
Mouse Immunization Schedule
BALB/c mice (6–8 weeks old) were purchased from Harlan. For
the heterologous DNA prime/MVA boost immunization protocol
performed to assay the immunogenicity of the MVA-C-DF1L
deletion mutant, groups of animals (n = 6) received 100 mg of
DNA-C (50 mg of pcDNA-CN54gp120+50 mg of
pcDNA-CN54GPN) or 100 mg of DNA-w (100 mg of pcDNA) by
intramuscular route (i.m.). Two weeks later, animals were
immunized with 16107 PFU of MVA wt, MVA-C or MVA-C-
DF1L by intraperitoneal route (i.p.). Mice immunized with sham
DNA (DNA-w) followed by MVA wt boost were used as control
group. At 10 and 53 days after the last immunization, 3 mice in
each group were sacrificed and spleens processed for Intracellular
Cytokine Staining (ICS) assay to measure the adaptive and
memory cellular immune responses against HIV-1 antigens,
respectively. Two independent experiments have been performed
for the different groups.
Intracellular Cytokine Staining Assay (ICS)
The magnitude, polyfunctionality and phenotype of the HIV-1
specific T cell responses were analyzed by ICS. After an overnight
rest, 46106 splenocytes (depleted of red blood cells) were seeded
on 96-well plates and stimulated during 6 hours in complete RPMI
1640 media supplemented with 10% FCS containing 1 ml/ml
GolgiPlug (BD Biosciences) and 20 mg/ml, 5 mg/ml or 10 mg/ml
of the HIV-1 peptides Env-1, Pol-1 or Pol-2, respectively. At the
end of the stimulation period, cells were washed, stained for the
surface markers, fixed and permeabilized (Cytofix/Cytoperm Kit;
BD Biosciences) and stained intracellularly using the appropriate
fluorochromes. Dead cells were excluded using the violet LIVE/
DEAD stain kit (Invitrogen). For functional analyses the following
fluorochromes-conjugated antibodies were used: CD4-Alexa 700,
CD8–FITC, IFN-c-PE-Cy7, IL-2-APC, TNF-a-PE-Cy7 (all from
BD Biosciences), CD3-FITC (Beckman Coulter), CD8-PerCP
(BioLegend), IFN-c-APC and IL-2-PE (both from eBioscience). In
addition, for phenotypic analyses the following antibodies were
used: CD62L-PE (SouthernBiotech) and CD44-SPRD (Beckman
Coulter). Cells were acquired using an LSRII flow cytometer (BD
Biosciences). Analyses of the data were performed using the
FlowJo software version 8.5.3 (Tree Star, Ashland, OR). The
number of lymphocyte-gated events ranged between 16105 and
16106. After gating, Boolean combinations of single functional
gates were then created using FlowJo software to determine the
frequency of each response based on all possible combinations of
cytokine expression or all possible combinations of differentiation
marker expression. Background responses detected in negative
control samples were subtracted from those detected in stimulated
samples for every specific functional combination.
ELISPOT Assay
The Gag-specific adaptive cellular immune response was
evaluated 10 days after the last immunization in a fresh IFN-c
enzyme-linked immunosorbent spot (ELISPOT) assay as pre-
viously described [88]. The HIV-1 peptide pools were resus-
pended in RPMI 1640 supplemented with 10% FCS and added to
cells at a final concentration of 5 mg/ml.
Data Analysis and Statistics
For the statistical analysis of ICS data, we used a novel
approach that corrects measurements for the medium response
(RPMI) and allows the calculation of confidence intervals and p
values of hypothesis tests [57,89]. Only antigen responses values
significantly higher than the corresponding RPMI are represented
and the background for the different cytokines in the unstimulated
controls never exceeded 0.05%. The data analysis program,
Simplified Presentation of Incredibly Complex Evaluations
(SPICE, version 4.1.5, Mario Roederer, Vaccine Research Center,
NIAID, NIH), was used to analyze and generate graphical
representations of T cell responses detected by polychromatic flow
cytometry. All values used for analyzing proportionate represen-
tation of responses are background-subtracted. For the analysis of
Annexin V binding assay data, we used the same statistical
procedure with minor modifications according to the specific
experimental approach.
For the comparison of the ratio between adaptive and memory
immune responses (contraction fold), we have developed a tech-
nique based on that previously reported [89]. Let us call NT the
total number of cells being analyzed, and NAg the number of cells
responding to a given antigen. As in [89] we assume that the
estimate of the proportion of cells responding to the antigen, p^Ag,
follows a Beta distribution with parameters
(NAgz1,NT{NAgz1). Let us call fp^Ag (x)the probability density
function associated to the proportion estimate. Analogously, we
estimate the background response as the proportion of cells
responding to the medium alone (RPMI), p^RPMI (being fp^RPMI (x)
its corresponding probability density function). We define the
corrected proportion asp^AgCorrected~p^Ag{p^RPMI . The probability
density function of this new estimate is given by standard statistical
rules, fp^AgCorrected (x)~
Ð?
{?
fp^Ag (x)fp^RPMI (xzx)dx. This corrected
estimate of the proportion and its distribution are computed for
the adaptive and memory responses. Then, we can compute the
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response contraction ratio as rAdaptive,Memory~
p^AgCorrectedAdaptive
p^AgCorrectedMemory
, whose
statistical distribution is given by
frAdaptive,Memory (x)~
Ð?
{?
DxDfp^AgCorrectedAdaptive (xx)fp^AgCorrectedMemory (x)dx. Fi-
nally, we compute the statistical distribution of the differences
between the contraction ratio for different kind of virus strains.
diffStrain1,Strain2~rAdaptive,Memory,Strain1{rAdaptive,Memory,Strain2. The
probability density function of this new variable is given by
fdiffStrain1,Strain2 (x)~
Ð?
{?
frAdaptive,Memory,Strain1 (x)frAdaptive,Memory,Strain2 (x{x)dx.
The p value of the hypothesis that Strain 1 has a ratio significantly
larger than Strain 2 is given byp~~
Ð0
{?
fdiffStrain1,Strain2 (x)dx.
Supporting Information
Figure S1 CN54 clade C Gag-Pol-Nef sequence
(4254 bp). Cytosine-rich regions are depicted. GPN sequence
contains 14 sequences of 5 cytosines (solid line), 1 region of 8
cytosines (shaded; cytosine insertion in plaque 19) and 1 region of
6 cytosines (dotted line; cytosine insertion in plaque 26).
(TIF)
Figure S2 Adaptive Gag-specific T cell immune re-
sponse elicited by F1L deletion mutant. Magnitude of the
total Gag-specific T cell response was measured 10 days after the
last immunization by ELISPOT assay following stimulation with
the different HIV-1 peptide pools in 3 mice of each group (n = 3).
Number of IFN-c-secreting cells are represented. *** p,0.001. p
value indicates significantly higher response compared to DNA-C/
MVA-C immunization group.
(TIF)
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